In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse events.

Abstract	SOURCE CITATION: Fujiwara Y, Horita N, Adib E, et al. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 2024;25:62-75. 38012893.
Authors	Luca Bertolaccini
Journal	Annals of internal medicine (Ann Intern Med) Vol. 177 Issue 4 Pg. JC42 (Apr 2024) ISSN: 1539-3704 [Electronic] United States
PMID	38560904 (Publication Type: Meta-Analysis, Systematic Review, Journal Article)
Chemical References	Immune Checkpoint Inhibitors
Topics	Humans Immune Checkpoint Inhibitors (adverse effects) Neoadjuvant Therapy (adverse effects) Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!